Multidrug-resistant and extensively drug-resistant tuberculosis: consequences for the global HIV community.
about
Diabetes-related tuberculosis in the Middle East: an urgent need for regional research.Structural and Biochemical Characterization of Mycobacterium tuberculosis CYP142: EVIDENCE FOR MULTIPLE CHOLESTEROL 27-HYDROXYLASE ACTIVITIES IN A HUMAN PATHOGENSurvival from XDR-TB is associated with modifiable clinical characteristics in rural South AfricaOutcomes of comprehensive care for children empirically treated for multidrug-resistant tuberculosis in a setting of high HIV prevalenceDiagnosis and interim treatment outcomes from the first cohort of multidrug-resistant tuberculosis patients in Tanzania.Quantitative drug-susceptibility in patients treated for multidrug-resistant tuberculosis in Bangladesh: implications for regimen choice.Improvement in plasma drug activity during the early treatment interval among Tanzanian patients with multidrug-resistant tuberculosis.Individualizing management of extensively drug-resistant tuberculosis: diagnostics, treatment, and biomarkers.Outcomes and use of therapeutic drug monitoring in multidrug-resistant tuberculosis patients treated in virginia, 2009-2014Plasma drug activity in patients on treatment for multidrug-resistant tuberculosisUnderstanding pharmacokinetics to improve tuberculosis treatment outcome.Comparison of overnight pooled and standard sputum collection method for patients with suspected pulmonary tuberculosis in northern Tanzania.Extensively drug-resistant Mycobacterium tuberculosis from aspirates, Rural South Africa.Extensively drug-resistant tuberculosis in children with human immunodeficiency virus in rural South Africa.Blood cultures for the diagnosis of multidrug-resistant and extensively drug-resistant tuberculosis among HIV-infected patients from rural South Africa: a cross-sectional study.The future of molecular diagnostics for drug-resistant tuberculosis.Clinical isolates of Mycobacterium tuberculosis in four European hospitals are uniformly susceptible to benzothiazinonesOutcomes of multidrug-resistant tuberculosis treatment with early initiation of antiretroviral therapy for HIV co-infected patients in Lesotho.Timing of antiretroviral therapy for HIV in the setting of TB treatment.Transmission of drug-susceptible and drug-resistant tuberculosis and the critical importance of airborne infection control in the era of HIV infection and highly active antiretroviral therapy rolloutsRifampin, but not rifabutin, may produce opiate withdrawal in buprenorphine-maintained patientsInhibition of glutamine synthetase: a potential drug target in Mycobacterium tuberculosis.Programmatic and ethical challenges in the implementation of treatment-as-prevention in the context of HIV and drug-resistant tuberculosis co-infection in sub-Saharan Africa.Drug-resistant tuberculosis: pediatric guidelines.Protein tyrosine kinase, PtkA, is required for Mycobacterium tuberculosis growth in macrophages.Ureidopyrazine Derivatives: Synthesis and Biological Evaluation as Anti-Infectives and Abiotic Elicitors.
P2860
Q26786671-B590A660-37ED-41CF-BF81-19985D1738DAQ27664866-4CBABEFC-BB1A-48C9-92F1-E094F9F52219Q28481405-1A729E34-BAEB-41A3-8267-C7C3E00A4FA7Q28483868-BC227EDD-6914-498A-A017-D1E1DF9432A6Q28487970-86D4283B-07F7-4ED1-A93F-9D546F05C1CAQ28543642-233A0D5E-F0F5-48C2-9A9D-C866C2678E15Q28545109-D506CBEF-A0B4-4FD5-A9FD-C9F7E939175AQ30275673-90B48816-45DF-4BC9-A773-FF3D6930B416Q30300207-46F409B6-2E3A-48E8-8E7B-B61C476FCB10Q30411475-5DA1AFCE-F7B2-46BD-9314-371AF7F2CAFBQ30411703-B53228B7-3D38-4D81-AE63-F7AF1D9B9BBAQ30426985-1A0D4F93-5AF9-4B8C-8520-AEFC5AF59343Q30427302-AF7200BD-BC60-415C-95F1-F157A91AB33BQ30433414-29CB4236-0DCA-494E-ACAC-A54C81259449Q30433540-FF1C8B0C-7C34-476E-933D-59F5DE8A996AQ30455525-9853895A-4310-4BAA-8374-4F4AB409A6EDQ33768910-5C7B90DE-3B54-4D56-9210-BDCACCB7DCD1Q34463467-F40B04AA-B939-4D4B-AE10-27752E03C923Q34475542-98FC6CBD-CA4F-4051-A23F-7F111ECE7991Q34530427-3DA0C6DC-3446-4EE4-8DB6-175E064BF49CQ35738885-3E1CACEC-C12B-480B-9DB2-C1A7ECBA0428Q38243884-5AF3ED92-2FBF-4FB1-97E6-FA19E217BDAEQ38393167-DEDDDDDF-5296-4E0E-B70C-9444B746615DQ45014161-C26BDD19-937A-4E57-834E-E62200CA90C6Q47215563-D6C248B4-6880-4AB5-AE5E-E928A1287635Q48135432-0E9FBCEF-0773-4EE6-B5CF-DB09D5A67C79
P2860
Multidrug-resistant and extensively drug-resistant tuberculosis: consequences for the global HIV community.
description
2009 nî lūn-bûn
@nan
2009 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
2009 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
2009年の論文
@ja
2009年論文
@yue
2009年論文
@zh-hant
2009年論文
@zh-hk
2009年論文
@zh-mo
2009年論文
@zh-tw
2009年论文
@wuu
name
Multidrug-resistant and extens ...... for the global HIV community.
@ast
Multidrug-resistant and extens ...... for the global HIV community.
@en
Multidrug-resistant and extens ...... for the global HIV community.
@nl
type
label
Multidrug-resistant and extens ...... for the global HIV community.
@ast
Multidrug-resistant and extens ...... for the global HIV community.
@en
Multidrug-resistant and extens ...... for the global HIV community.
@nl
prefLabel
Multidrug-resistant and extens ...... for the global HIV community.
@ast
Multidrug-resistant and extens ...... for the global HIV community.
@en
Multidrug-resistant and extens ...... for the global HIV community.
@nl
P2093
P2860
P1476
Multidrug-resistant and extens ...... for the global HIV community.
@en
P2093
Anthony Moll
Gerald Friedland
Scott Heysell
P2860
P356
10.1097/QCO.0B013E3283210020
P577
2009-02-01T00:00:00Z